CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Operating expenses:
Research and development	$ 27,606	$ 16,875	$ 73,418	$ 47,488
General and administrative	7,710	7,226	24,494	21,205
Total operating expenses	35,316	24,101	97,912	68,693
Loss from operations	(35,316)	(24,101)	(97,912)	(68,693)
Other income:
Interest income	2,126	313	6,310	509
Total other income	2,126	313	6,310	509
Net loss	$ (33,190)	$ (23,788)	$ (91,602)	$ (68,184)
Net loss per share attributable to common stockholders, basic	$ (0.49)	$ (0.63)	$ (1.37)	$ (1.81)
Net loss per share attributable to common stockholders, diluted	$ (0.49)	$ (0.63)	$ (1.37)	$ (1.81)
Weighted-average number of common shares outstanding, basic	67,607,713	38,009,022	66,973,771	37,582,463
Weighted-average number of common shares outstanding, diluted	67,607,713	38,009,022	66,973,771	37,582,463
Other comprehensive income (loss):
Unrealized gain (loss) on available for sale investments	$ 156	$ 148	$ 490	$ (1,178)
Total other comprehensive income (loss)	156	148	490	(1,178)
Comprehensive loss	$ (33,034)	$ (23,640)	$ (91,112)	$ (69,362)